X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The net proceeds will be used for the development of SBP-101 (ivospemin), which is designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 01, 2024
Details:
The net proceeds will be used for the development of SBP-101 (ivospemin), which is designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 29, 2024
Details:
The company intends to use the net proceeds for the clinical development of SBP-101 (ivospemin), which is designed to induce polyamine metabolic inhibition (PMI) for metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 29, 2024
Details:
SBP-101 (ivospemin) is a small molecule AMD1/ODC1 inhibitor. It is being evaluated in phase 2/3 clinical trials in combination with gemcitabine & nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2024
Details:
SBP-101 (ivospemin) is a small molecule AMD1/ODC1 inhibitor. It is being evaluated in phase 3 clinical trials in combination with gemcitabine & nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
SBP-101 (ivospemin) is a polyamine analogue designed to induce polyamine metabolic inhibition by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
SBP-101 (ivospemin) is a polyamine analogue designed to induce polyamine metabolic inhibition by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
The Company intends to use the net proceeds for the continued clinical development of its product candidates including, SBP-101 (ivospemin), a proprietary polyamine analogue, being developed for the traetment of pancreatic ductal adenocarcinoma.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $8.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 16, 2023
Details:
The collaboration aims for the evaluation of polyamine metabolic inhibitor therapies involving, SBP-101 (ivospemin), in combination with CAR-T cell therapies in preclinical models.
Lead Product(s): Ivospemin,CAR T-cell Therapy
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 13, 2023
Details:
The collaboration is intended to expand the development of Panbela’s investigative agent SBP-101 (ivospemin), including activity in models of ovarian and other cancer types, further evaluations into MOA, and potential combination with CPP-1X and standard of care agents.
Lead Product(s): Ivospemin,Eflornithine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johns Hopkins University School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 03, 2023
Details:
SBP-101 (ivospemin) is a polyamine analogue designed to induce polyamine metabolic inhibition by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
Panbela intends to use the net proceeds from the offering for the continued clinical development of its product candidates SBP-101 (ivospemin) and CPP-1X (eflornithine), working capital, business development and other general corporate purposes.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 13, 2023
Details:
The Company intends to use the net proceeds from the proposed offering for the continued clinical development of its product candidates SBP-101 (ivospemin) and CPP-1X (eflornithine), working capital, business development and other general corporate purposes.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 26, 2023
Details:
SBP-101 (ivospemin) is a polyamine analogue designed to induce polyamine metabolic inhibition by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
Ivospemin (SBP-101), is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Details:
SBP-101 (Ivospemin), is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
The Company intends to use the net proceeds from the proposed offering for the continued clinical development of its product candidates ivospemin (SBP-101) and eflornithine (CPP-1X), working capital, business development and other general corporate purposes.
Lead Product(s): Ivospemin,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
